Litigation & Dispute Resolution partner Chris Kelly (Palo Alto) is quoted in an article discussing that attorneys believe that the US Federal Trade Commission's newly finalized rule requiring pharmaceutical companies to report more exclusive patent licenses for antitrust approval under the Hart-Scott-Rodino Act will increase costs and delays for the industry.

Downloads –